 |
|
|
| |
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and
Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-12 Boston
Robert J Fontana1, Sabela Lens2, Stuart McPherson3, Magdy Elkhashab4, Krum Katzarov5, Ana Gabriela Pires dos Santos6, Zhenyi Xue6, Roger Trinh6, Lino Rodrigues Junior6, Ariel Porcalla6, Stefan Zeuzem7
1Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, United States; 2Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, Barcelona, Spain; 3Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundati on and Trust and Newcastle University, United Kingdom;
4Toronto Liver Centre, Toronto, Ontario, Canada; 5Department of Gastroenterology, Hepato-Pancreato-Biliary (HPB) Surgery and Transplantology, Military Medical Academy, Sofi a, Bulgaria; 6AbbVie Inc., North Chicago, Illinois, United States; 7JW Goethe University, Frankfurt, Germany
|
| |
|
|
|
|
|
